AGLE Aeglea BioTherapeutics Inc.

4.86
+0.13  (3%)
Previous Close 4.73
Open 4.94
Price To book 1.28
Market Cap 79957984
Shares 16,452,260
Volume 28,452
Short Ratio 0.87
Av. Daily Volume 57,029

SEC filingsSee all SEC filings

  1. 8-K - Current report 171074385
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017829
  3. 8-K - Current report 171017792
  4. 8-K - Current report 17974422
  5. 8-K - Current report 17903184

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 1/2 dosing in repeat dose part (Part 2) announced September 6, 2017. Top-line data due 2H 2018.
AEB1102
Arginase I deficiency

SEC Filings

  1. 8-K - Current report 171074385
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017829
  3. 8-K - Current report 171017792
  4. 8-K - Current report 17974422
  5. 8-K - Current report 17903184
  6. 8-K - Current report 17894244
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17894214
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17891196
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17881116
  10. EFFECT - Notice of Effectiveness 17879367